Literature DB >> 12866583

Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer.

T Fukushima1, M Mashiko, K Takita, T Otake, Y Endo, K Sekikawa, S Takenoshita.   

Abstract

Transforming growth factor-beta(TGF-beta) is known to play an important role in controlling embryonal development, cell proliferation and homeostasis. The purpose of this study is to elucidate the involvement of the TGF-beta pathway in colorectal carcinogenesis. DNA was extracted from 100 patients with colorectal cancer. Then, all coding regions of the TGF-beta type II receptor (TRII) and the genes for Smad2, Smad3, Smad4, Smad6, and Smad7 were analyzed by PCR-SSCP and direct sequencing. Also, a LOH analysis of 18q21, where the Smad2 and Smad4 genes are located, was performed. We detected 11 cases of frameshift mutation in the TRII gene (11%) and 5 cases of point mutations in the Smad4 gene (5.0%); LOH at 18q21 was detected with 33% frequency. No abnormalities were found in the genes for Smad2, Smad3, Smad6, and Smad7. These results suggest that the abnormalities of TRII and Smad4 play an important role inhibiting TGF-beta signaling in colorectal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866583

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  12 in total

1.  MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-β RII.

Authors:  Xiaofeng Jiang; Guangyang Xiang; Yezeng Wang; Lei Zhang; Xuewei Yang; Liangqi Cao; Heping Peng; Ping Xue; De Chen
Journal:  Mol Cells       Date:  2012-06-07       Impact factor: 5.034

2.  Common colorectal cancer risk variants in SMAD7 are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: a population-based study of postmenopausal women.

Authors:  Michael N Passarelli; Anna E Coghill; Carolyn M Hutter; Yingye Zheng; Karen W Makar; John D Potter; Polly A Newcomb
Journal:  Genes Chromosomes Cancer       Date:  2011-08-24       Impact factor: 5.006

Review 3.  Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk.

Authors:  Amal Ahmed Abd El-Fattah; Nermin Abdel Hamid Sadik; Olfat Gamil Shaker; Amal Mohamed Kamal
Journal:  Mediators Inflamm       Date:  2018-10-25       Impact factor: 4.711

4.  Genetic and pathologic changes associated with lymphovascular invasion of colorectal adenocarcinoma.

Authors:  Jin C Kim; Seon A Roh; Kang H Lee; Hwan Namgung; Jung R Kim; Jung S Kim
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  Smad7 Is Highly Expressed in Human Degenerative Discs and Participates in IL-1β-Induced Apoptosis of Rat AF Cells via the Mitochondria Pathway.

Authors:  Bo Li; Ze-Yu Lu; Sheng-Dan Jiang; Lei-Sheng Jiang; Xin-Feng Zheng
Journal:  Oxid Med Cell Longev       Date:  2022-06-26       Impact factor: 7.310

6.  Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer.

Authors:  D W Chan; V W S Liu; R M Y To; P M Chiu; W Y W Lee; K M Yao; A N Y Cheung; H Y S Ngan
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

7.  A genetic variant in microRNA target site of TGF-β signaling pathway increases the risk of colorectal cancer in a Chinese population.

Authors:  Jing Gong; Na Shen; Hong-Mei Zhang; Rong Zhong; Wei Chen; Xiaoping Miao; An-Yuan Guo
Journal:  Tumour Biol       Date:  2013-12-29

Review 8.  Alterations in the Smad pathway in human cancers.

Authors:  Debangshu Samanta; Pran K Datta
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

9.  Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Amr Mohamed Mohamed; Osama Adnan Kensara; Jawwad Ahmad; Shakir Idris
Journal:  BMC Cancer       Date:  2016-11-11       Impact factor: 4.430

Review 10.  The Roles of TIF1γ in Cancer.

Authors:  Chengpeng Yu; Zeyang Ding; Huifang Liang; Bixiang Zhang; Xiaoping Chen
Journal:  Front Oncol       Date:  2019-10-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.